Assessing the effects of radiotherapy on tumors in cervical and pancreatic cancer
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)
This study is testing how radiotherapy affects tumors in patients with locally advanced cervical and pancreatic cancer by collecting samples and using special imaging before, during, and after treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT05975593 on ClinicalTrials.gov |
What this trial studies
This study is a prospective longitudinal assessment aimed at capturing biospecimens and treatment-related data from patients undergoing definitive-intent chemoradiotherapy for locally advanced cervical and pancreatic cancer. It involves collecting tumor biopsies, blood samples, and utilizing diffusion basis spectrum imaging (DBSI) MRI to evaluate the tumor microenvironment before, during, and after treatment. The study is designed to adapt dynamically based on the data collected, providing a comprehensive understanding of the effects of radiotherapy on these cancers.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been confirmed to receive radiotherapy for locally advanced cervical or pancreatic cancer.
Not a fit: Patients with medical or anatomical issues that prevent safe acquisition of biospecimens may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients with locally advanced cervical and pancreatic cancers.
How similar studies have performed: Other studies have shown success in utilizing similar approaches to assess treatment effects in cancer, indicating potential for meaningful insights from this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmation of intent to receive radiotherapy for one of the following diagnoses: * Cervical cancer * Pancreatic cancer * ECOG performance status ≤ 2 * At least 18 years old * Able to understand and willing to sign an IRB-approved written informed consent document Exclusion Criteria: * Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Cliff Robinson, M.D. — Washington University School of Medicine
- Study coordinator: Cliff Robinson, M.D.
- Email: clifford.robinson@wustl.edu
- Phone: 314-362-8567
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.